LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able:

• To understand the role of the antibody Fc domain in modulating the activity of therapeutic antibodies, and to discuss how Fc-engineering strategies contribute to the development  of next-generation cancer immunotherapies
• To highlight the potential of targeting myeloid immune receptors to enhance antitumor immunity
• To analyze the mechanisms underlying the activity of myeloid-targeting antibodies, such anti-CD47 and anti-CD40 antibodies, and their impact on innate and adaptive immune responses in preclinical and clinical settings